Vaccines (Basel)
November 2024
European countries have included healthcare workers (HCWs) among priority groups for COVID-19 vaccination. We established a multi-country hospital network to measure the SARS-CoV-2 incidence and effectiveness of COVID-19 vaccines among HCWs against laboratory-confirmed SARS-CoV-2 infection. HCWs from 19 hospitals in 10 countries participated in a dynamic prospective cohort study, providing samples for SARS-CoV-2 testing at enrolment and during weekly/fortnightly follow-up.
View Article and Find Full Text PDFInfluenza Other Respir Viruses
November 2024
We estimated XBB.1.5 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection among adults aged ≥ 65 years during the 2023/2024 JN.
View Article and Find Full Text PDFInfluenza Other Respir Viruses
August 2024
Background: By March, 2023, 54 countries, areas, and territories (hereafter CAT) in the WHO European Region had reported more than 2·2 million COVID-19-related deaths to the WHO Regional Office for Europe. Here, we estimated how many lives were directly saved by vaccinating adults in the WHO European Region from December, 2020, to March, 2023.
Methods: In this retrospective surveillance study, we estimated the number of lives directly saved by age group, vaccine dose, and circulating variant-of-concern (VOC) period, regionally and nationally, using weekly data on COVID-19 mortality and infection, COVID-19 vaccination uptake, and SARS-CoV-2 virus characterisations by lineage downloaded from The European Surveillance System on June 11, 2023, as well as vaccine effectiveness data from the literature.
In autumn 2023, European vaccination campaigns predominantly administered XBB.1.5 vaccine.
View Article and Find Full Text PDFBackgroundScarce European data in early 2021 suggested lower vaccine effectiveness (VE) against SARS-CoV-2 Omicron lineages than previous variants.AimWe aimed to estimate primary series (PS) and first booster VE against symptomatic BA.1/BA.
View Article and Find Full Text PDFWe conducted a multicentre hospital-based test-negative case-control study to measure vaccine effectiveness (VE) against PCR-confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022/2023 influenza season in Europe. Among 5547 SARI patients ≥18 years, 2963 (53%) were vaccinated against influenza. Overall VE against influenza A(H1N1)pdm09 was 11% (95% CI: -23-36); 20% (95% CI: -4-39) against A(H3N2) and 56% (95% CI: 22-75) against B.
View Article and Find Full Text PDFInfluenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2).
View Article and Find Full Text PDFWe conducted a multicentre hospital-based test-negative case-control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during the Omicron XBB lineage-predominant period in patients aged ≥ 60 years with severe acute respiratory infection from five countries in Europe. Bivalent vaccines provided short-term additional protection compared with those vaccinated > 6 months before the campaign: from 80% (95% CI: 50 to 94) for 14-89 days post-vaccination, 15% (95% CI: -12 to 35) at 90-179 days, and lower to no effect thereafter.
View Article and Find Full Text PDFNanoparticles of NiLaFeO ferrite spinel incorporated in a SiO matrix were synthesized via a sol-gel method, followed by annealing at 200, 500, and 800 °C. The resulting materials were characterized via XRD, AFM, and BET techniques and evaluated for photocatalytic activity. The XRD diffractograms validate the formation of a single-phase cubic spinel structure at all temperatures, without any evidence of secondary peaks.
View Article and Find Full Text PDFInfluenza Other Respir Viruses
November 2023
Euro Surveill
November 2023
IntroductionTwo large multicentre European hospital networks have estimated vaccine effectiveness (VE) against COVID-19 since 2021.AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients ≥ 20 years, combining data from these networks during Alpha (March-June)- and Delta (June-December)-dominant periods, 2021.MethodsForty-six participating hospitals across 14 countries follow a similar generic protocol using the test-negative case-control design.
View Article and Find Full Text PDFEuro Surveill
November 2023
Measles cases have recently been increasing in Romania, with 460 confirmed cases by August 2023. From March 2023, measles cases increased, and outbreaks were recorded in Cluj, Bistrita Nasaud, Sibiu and Mures counties. New D8 virus variants were identified, different from the variants detected in Romania before the COVID-19 pandemic.
View Article and Find Full Text PDFIntroduction: An unusual cluster of myoclonic epilepsy was observed in a Romanian pediatric HIV cohort concurrent with measles outbreaks. We describe this particular form of subacute measles encephalitis (SME) in a group of HIV-infected children and adolescents with severe immunosuppression.
Methods: This is a single-center study, starting in 1997 and covering 4 measles outbreaks in Romania.
(CoZnNiFeO)(SiO) samples obtained by embedding CoZnNiFeO nanoparticles in SiO in various proportions were synthesized by sol-gel process and characterized using thermal analysis, Fourier-transform infrared spectroscopy, X-ray diffraction, transmission electron microscopy, inductively coupled plasma optical emission spectrometry, and magnetic measurements. Poorly crystalline Co-Zn-Ni ferrite at low annealing temperatures (500 °C) and highly crystalline Co-Zn-Ni ferrite together with traces of crystalline FeSiO (800 °C) and SiO (tridymite and cristobalite) (1200 °C) were obtained. At 1200 °C, large spherical particles with size increasing with the ferrite content (36-120 nm) were obtained.
View Article and Find Full Text PDFWe report the case of a 34-year-old male patient, a bodybuilding trainer and user of anabolic androgenic steroids (AASs) for 16 years. He was found in cardio-respiratory arrest in his home. By performing a medico-legal autopsy, a severe form of COVID-19, aortic atherosclerotic plaques, and an old myocardial infarction was found.
View Article and Find Full Text PDFIn the context of an increased interest in the abatement of CO emissions generated by industrial activities, CO hydrogenation processes show an important potential to be used for the production of valuable compounds (methane, methanol, formic acid, light olefins, aromatics, syngas and/or synthetic fuels), with important benefits for the decarbonization of the energy sector. However, in order to increase the efficiency of the CO hydrogenation processes, the selection of active and selective catalysts is of utmost importance. In this context, the interest in graphene-based materials as catalysts for CO hydrogenation has significantly increased in the last years.
View Article and Find Full Text PDF